CLEVELAND, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Chart Industries, Inc. (NASDAQ:GTLS), a leading diversified global manufacturer of highly engineered equipment for the industrial gas, energy and biomedical industries, today reported results for the third quarter ended September 30, 2016.  Highlights include:
  • Continued strong operating cash flow of $59.8 million
  • Successful recovery of past BioMedical warranty related costs contributed $16.0 million to net income
  • Downstream European LNG demand continues for Distribution & Storage

Net income for the third quarter of 2016 was $15.0 million, or $0.48 per diluted share.  Third quarter 2016 earnings would have been $0.53 per diluted share excluding $1.5 million, or $0.05 per diluted share, of asset impairment, restructuring and acquisition-related costs.  This compares with net income of $4.8 million, or $0.15 per diluted share, for the third quarter of 2015.  Third quarter 2015 earnings would have been $0.26 per diluted share excluding $4.9 million, or $0.11 per diluted share, of facility shutdown, restructuring and acquisition-related costs.

Net sales for the third quarter of 2016 decreased 22.8% to $203.9 million from $264.0 million in the comparable period a year ago, primarily due to the slowdown seen in the energy markets.  Gross profit for the third quarter of 2016 was $69.6 million, or 34.1% of sales, which was favorably impacted by the insurance recovery, compared to gross profit for the third quarter of 2015 of $68.3 million, or 25.9% of sales.

"Distribution & Storage ("D&S") continues to see good order flow for downstream LNG terminals in Europe, although our third quarter results were negatively impacted by the continued energy market slowdown seen in our Energy & Chemicals ("E&C") business.  During the quarter, we also benefited from successful recovery of past warranty related costs in our BioMedical business," stated Sam Thomas, Chart's Chairman and Chief Executive Officer.

Mr. Thomas added, "This insurance recovery represents partial recovery of losses BioMedical suffered over the last several years driven by worse than anticipated warranty experience in AirSep product lines.  We have corrected the issue and our current warranty expense is more indicative of what we expect in the future.  Under Bill Johnson's leadership, we are focusing heavily on our operations, implementing further productivity improvements and identifying profit-driven initiatives to better position ourselves.  In addition, our strong balance sheet gives us significant flexibility to pursue some exciting organic and inorganic investment opportunities to grow our business."

Orders received in the third quarter of 2016 were $201.2 million, a decrease of $69.0 million over orders received during the second quarter of 2016, which included a number of large awards within all three of our reporting segments.  Despite new orders for our Lifecycle business, E&C orders continue to be negatively impacted by a weak energy market in addition to $5 million in project cancellations in the quarter.  Backlog at September 30, 2016 was $384.4 million, down 2.1% from the June 30, 2016 level of $392.5 million.

Selling, general and administrative ("SG&A") expenses for the third quarter of 2016 decreased $2.7 million compared with the same period in 2015 to $45.4 million, or 22.3% of sales.  Lower payroll and other discretionary spending were partially offset by variable short-term compensation as a result of improved earnings in the current quarter.  The prior year quarter included $3.9 million in facility shutdown and severance costs associated with cost reduction initiatives. 

Third quarter of 2016 includes $1.2 million of asset impairment charges related to our D&S Asia business.

Income tax expense was $1.8 million for the third quarter of 2016 and represented an effective tax rate of 11.4% compared with $6.1 million in the prior year quarter, or an effective tax rate of 58.8%.  The effective tax rate for the current quarter is lower than 2015's third quarter rate primarily due to the insurance recovery which is not currently taxable.  The prior year quarter's rate was unusually high as a result of a reserve against certain accumulated tax loss balances, which made up 15 percentage points in the prior year quarter.

Net interest expense was $4.3 million for the third quarter of 2016, which included $3.2 million of non-cash accretion expense associated with the Company's Convertible Notes.  Net cash interest expense was $1.1 million.

Cash and short-term investments of $267.3 million have increased $54.1 million since June 30, 2016 due to strong operating cash flow generation which includes the insurance recovery proceeds.

SEGMENT HIGHLIGHTS

E&C segment sales decreased 69.8% to $23.7 million for the third quarter of 2016 compared with $78.4 million for the same quarter in the prior year.  Lower sales volume was seen across all product lines given continued challenging energy market conditions.  E&C gross profit margins were 7.6% in the 2016 quarter compared with 23.4% in the same quarter of 2015 due to low volume and competitive market conditions.

D&S segment sales decreased 2.3% to $126.6 million for the third quarter of 2016 compared with $129.6 million for the same quarter in the prior year.  Revenues in LNG applications are down this quarter in Asia and in the U.S., but Europe is up somewhat versus the prior year quarter, reflecting continued downstream LNG activity.  D&S gross profit margins were 26.4% compared with 23.9% in the prior year quarter due to lower restructuring costs and improved throughput in the current quarter.

BioMedical segment sales decreased 4.5% to $53.6 million for the third quarter of 2016 compared with $56.1 million for the same quarter in the prior year.  The decrease is primarily due to lower revenues in respiratory and commercial oxygen generation, partially offset by an increase in life sciences.  BioMedical gross profit margin increased to 64.2% in the quarter compared with 33.8% for the same period in 2015 driven by the insurance recovery for breaches of representations and warranties primarily related to warranty costs for certain product lines acquired during the AirSep acquisition in 2012, which added 28.3% to the margin in the current quarter.  Exclusive of the recovery, the margin improved quarter over quarter due to lower warranty expense and improved product mix of life science products.

OUTLOOK

Based on year-to-date results, we are narrowing our 2016 sales guidance with sales expected to be in the range of $850 million to $875 million.  Additionally, we are raising full year adjusted earnings per diluted share (non-GAAP) guidance which is expected to be in the range of $1.20 to $1.30 per share, on approximately 31.1 million weighted average shares outstanding.  This revised guidance compares with previous sales guidance of $850 million to $900 million and earnings of $0.75 to $0.95 per diluted share, which excluded restructuring costs.  Adjusted earnings per diluted share is a non-GAAP measure, which excludes the impact from certain restructuring, impairment and acquisition-related costs.

FORWARD-LOOKING STATEMENTS

Certain statements made in this news release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements include statements concerning the Company's plans, objectives, future orders, revenues, earnings or performance, liquidity and cash flow, capital expenditures, business trends, and other information that is not historical in nature.  Forward-looking statements may be identified by terminology such as "may," "will," "should," "could," "expects," "anticipates," "believes," "projects," "forecasts," "outlook," "guidance," "continue," or the negative of such terms or comparable terminology.

Forward-looking statements contained in this news release or in other statements made by the Company are made based on management's expectations and beliefs concerning future events impacting the Company and are subject to uncertainties and factors relating to the Company's operations and business environment, all of which are difficult to predict and many of which are beyond the Company's control, that could cause the Company's actual results to differ materially from those matters expressed or implied by forward-looking statements.  These factors and uncertainties include, among others, the following: the cyclicality of the markets that the Company serves and the vulnerability of those markets to economic downturns; a delay, significant reduction in or loss of purchases by large customers; fluctuations in energy prices; our ability to control our costs and successfully manage our operations; a delay in the anticipated timing of LNG infrastructure build out or a delay or failure to receive orders; the potential for negative developments in the natural gas industry related to hydraulic fracturing; competition; potential future impairment of the Company's significant goodwill and other intangibles; changes in government energy policy or the failure of expected changes in policy to materialize; variability in operating results associated with unanticipated increases in warranty returns of Company products; the modification or cancellation of orders in our backlog; loss of key employees; challenges and uncertainties associated with efforts to acquire and integrate product lines or businesses; economic downturns and deteriorating financial conditions; our ability to manage our fixed-price contract exposure; our reliance on key suppliers and potential supplier failures or defects; fluctuations or adjustments in the Company's effective tax rate; changes in government healthcare regulations and reimbursement policies; litigation and disputes involving the Company, including product liability, contract, warranty, intellectual property, employment and environmental claims; fluctuations in foreign currency exchange and interest rates; general economic, political, business and market risks associated with the Company's international operations and transactions; technological security threats; financial distress of third parties; our ability to protect our intellectual property; the regulation of our products by the U.S. Food & Drug Administration and other governmental authorities; the pricing and availability of raw materials; the cost of compliance with environmental, health and safety laws; claims that our products or processes infringe intellectual property rights of others; additional liabilities related to taxes; deterioration of employee or labor relations; increased governmental regulation; risks associated with our indebtedness, leverage and liquidity; and volatility and fluctuations in the price of the Company's stock.

For a discussion of these and additional factors that could cause actual results to differ from those described in the forward-looking statements, see the Company's filings with the Securities and Exchange Commission, including Item 1A (Risk Factors) in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which should be reviewed carefully.  The Company undertakes no obligation to update or revise any forward-looking statement.

Chart is a leading diversified global manufacturer of highly engineered equipment for the industrial gas, energy, and biomedical industries.  The majority of Chart's products are used throughout the liquid gas supply chain for purification, liquefaction, distribution, storage and end-use applications, a large portion of which are energy-related.  Chart has domestic operations located across the United States and an international presence in Asia, Australia, Europe and South America.  For more information, visit: http://www.chartindustries.com.

USE OF NON-GAAP FINANCIAL INFORMATION

To supplement the unaudited condensed consolidated financial statements presented in accordance with U.S. GAAP in this news release, certain non-GAAP financial measures as defined by SEC rules are used.  The Company believes these non-GAAP measures are of interest to investors and facilitate useful period-to-period comparisons of the Company's financial results, and this information is used by the Company in evaluating internal performance.  See the last page of this news release for a reconciliation of adjusted earnings per diluted share, a non-GAAP measure included in this release.

With respect to the Company's full year earnings outlook, the Company is not able to provide a reconciliation of the adjusted earnings per diluted share because certain items may have not yet occurred or are out of the Company's control and / or cannot be reasonably predicted.

CONFERENCE CALL

As previously announced, the Company will discuss its third quarter 2016 results on a conference call on Thursday, October 27, 2016 at 10:30 a.m. ET.  Participants may join the conference call by dialing (877) 312-9395 in the U.S. or (970) 315-0456 from outside the U.S.  A live webcast presentation will also be accessible at 10:30 a.m. ET at http://www.chartindustries.com.  Please log-in or dial-in at least five minutes prior to the start time.

A taped replay of the conference call will be archived on the Company's website, www.chartindustries.com, approximately one hour after the call concludes.  You may also listen to a taped replay of the conference call by dialing (855) 859-2056 in the U.S. or (404) 537-3406 outside the U.S. and entering Conference ID 98230977.  The telephone replay will be available beginning 1:30 p.m. ET, Thursday October 27, 2016 until 11:59 p.m. ET, Thursday, November 3, 2016.

For more information, click here:

http://ir.chartindustries.com/

CHART INDUSTRIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(UNAUDITED)
(Dollars and shares in thousands, except per share amounts)
 
        Three Months Ended September 30,       Nine Months Ended September 30,
        2016   2015       2016   2015
Sales       $ 203,930     $ 264,047         $ 644,782     $ 779,404  
Cost of sales       134,307     195,758         435,507     563,712  
Gross profit       69,623     68,289         209,275     215,692  
Selling, general and administrative expenses       45,430     48,108         143,862     146,898  
Amortization       2,912     4,572         9,156     13,099  
Asset impairment       1,217             1,217      
Operating expenses       49,559     52,680         154,235     159,997  
Operating income       20,064     15,609         55,040     55,695  
Other expenses:                        
Interest expense, net       4,291     4,073         12,556     11,994  
Financing costs amortization       321     322         963     969  
Foreign currency loss       4     848         117     771  
Other expenses, net       4,616     5,243         13,636     13,734  
Income before income taxes       15,448     10,366         41,404     41,961  
Income tax expense       1,764     6,095         12,829     15,333  
Net income       13,684     4,271         28,575     26,628  
Noncontrolling interests, net of taxes       (1,341 )   (489 )       (2,952 )   (535 )
Net income attributable to Chart Industries, Inc.       $ 15,025     $ 4,760         $ 31,527     $ 27,163  
Net income attributable to Chart Industries, Inc. per common share:                        
Basic       $ 0.49     $ 0.16         $ 1.03     $ 0.89  
Diluted       $ 0.48     $ 0.15         $ 1.02     $ 0.88  
Weighted average number of common shares outstanding:                        
Basic       30,585     30,498         30,578     30,487  
Diluted       31,064     30,745         30,940     30,693  
                         
Comprehensive income (loss), net of taxes       $ 13,932     $ (1,964 )       $ 29,235     $ 15,243  
Less: Comprehensive loss attributable to noncontrolling interests, net of taxes       (1,364 )   (762 )       (3,069 )   (803 )
Comprehensive income (loss) attributable to Chart Industries, Inc., net of taxes       $ 15,296     $ (1,202 )       $ 32,304     $ 16,046  
                                         

CHART INDUSTRIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(Dollars in thousands)
 
        Three Months Ended September 30,       Nine Months Ended September 30,
        2016   2015       2016   2015
Net Cash Provided By Operating Activities       $ 59,763     $ 46,431         $ 146,592     $ 54,425  
Investing Activities                        
Capital expenditures       (3,993 )   (11,587 )       (13,411 )   (36,066 )
Payments for land use rights                       (11,043 )
Proceeds from sale of assets           195             395  
Government grants       443             1,055      
Acquisition of businesses, net of cash acquired           (24,197 )       (1,383 )   (24,517 )
Net Cash Used In Investing Activities       (3,550 )   (35,589 )       (13,739 )   (71,231 )
Financing Activities                        
Borrowings on revolving credit facilities           56,450         3,820     68,827  
Repayments on revolving credit facilities       (2,245 )   (66,453 )       (6,061 )   (67,196 )
Borrowings on term loan                   13,167      
Repayments on term loan                   (1,508 )    
Proceeds from exercise of options       9     17         26     486  
Excess tax benefit from share-based compensation           3         54     133  
Payment of contingent consideration                       (611 )
Common stock repurchases       (15 )   (26 )       (658 )   (849 )
Dividend distribution to noncontrolling interests           (120 )           (120 )
Other financing activities           1             (156 )
Net Cash (Used In) Provided By Financing Activities       (2,251 )   (10,128 )       8,840     514  
Effect of exchange rate changes on cash       156     (1,062 )       1,875     (4,827 )
Net increase (decrease) in cash and cash equivalents       54,118     (348 )       143,568     (21,119 )
Cash and cash equivalents at beginning of period       213,158     82,885         123,708     103,656  
Cash and Cash Equivalents at End of Period       $ 267,276     $ 82,537         $ 267,276     $ 82,537  
                                         

CHART INDUSTRIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Dollars in thousands, except per share amounts)
 
        September 30,  2016   December 31,  2015
        (Unaudited)    
ASSETS            
Cash and cash equivalents       $ 267,276     $ 123,708  
Accounts receivable, net       132,556     183,514  
Inventories, net       182,227     199,302  
Other current assets       45,683     80,706  
Property, plant and equipment, net       258,081     266,277  
Goodwill       219,091     218,390  
Identifiable intangible assets, net       96,913     106,714  
Other assets       16,038     21,529  
TOTAL ASSETS       $ 1,217,865     $ 1,200,140  
             
LIABILITIES AND EQUITY            
Current liabilities       $ 224,600     $ 262,039  
Long-term debt       232,079     213,798  
Other long-term liabilities       48,855     48,567  
Equity       712,331     675,736  
TOTAL LIABILITIES AND EQUITY       $ 1,217,865     $ 1,200,140  
                     

CHART INDUSTRIES, INC. AND SUBSIDIARIES
OPERATING SEGMENTS (UNAUDITED)
(Dollars in thousands)
                               
  Three Months Ended September 30,   Nine Months Ended September 30,
  2016   2015   2016   2015
Sales              
Energy & Chemicals $ 23,711     $ 78,388     $ 122,865     $ 257,197  
Distribution & Storage 126,646     129,590     363,743     356,474  
BioMedical 53,573     56,069     158,174     165,733  
Total $ 203,930     $ 264,047     $ 644,782     $ 779,404  
Gross Profit (1)              
Energy & Chemicals $ 1,803     $ 18,345     $ 39,147     $ 70,888  
Distribution & Storage 33,429     30,984     96,074     89,517  
BioMedical 34,391     18,960     74,054     55,287  
Total $ 69,623     $ 68,289     $ 209,275     $ 215,692  
Gross Profit Margin              
Energy & Chemicals 7.6 %   23.4 %   31.9 %   27.6 %
Distribution & Storage 26.4 %   23.9 %   26.4 %   25.1 %
BioMedical 64.2 %   33.8 %   46.8 %   33.4 %
Total 34.1 %   25.9 %   32.5 %   27.7 %
Operating Income (Loss) (1)              
Energy & Chemicals $ (5,736 )   $ 10,795     $ 14,190     $ 45,626  
Distribution & Storage 14,715     8,027     37,550     29,184  
BioMedical 20,916     5,966     38,120     15,202  
Corporate (9,831 )   (9,179 )   (34,820 )   (34,317 )
Total $ 20,064     $ 15,609     $ 55,040     $ 55,695  
Operating Margin              
Energy & Chemicals (24.2 )%   13.8 %   11.5 %   17.7 %
Distribution & Storage 11.6 %   6.2 %   10.3 %   8.2 %
BioMedical 39 %   10.6 %   24.1 %   9.2 %
Total 9.8 %   5.9 %   8.5 %   7.1 %
_______________  
(1)  During the third quarter of 2016, the Company recovered for breaches of representations and warranties primarily related to warranty costs for certain product lines acquired in the 2012 acquisition of AirSep Corporation under the related representation and warranty insurance.  For the three months ended September 30, 2016, this reduced our BioMedical segment's cost of sales by $15,145 and Corporate SG&A expenses by $859, net of associated legal fees.  For the nine months ended September 30, 2016, this reduced our BioMedical segment's cost of sales by $15,145 and Corporate SG&A expenses by $376, net of associated legal fees recorded in the first nine months of the year.
 

CHART INDUSTRIES, INC. AND SUBSIDIARIES
ORDERS AND BACKLOG (UNAUDITED)
(Dollars in thousands)
                     
        Three Months Ended
        September 30,   June 30,
      2016 2016
Orders            
Energy & Chemicals       $ 27,889     $ 53,016  
Distribution & Storage       121,010     156,030  
BioMedical       52,347     61,221  
Total       $ 201,246     $ 270,267  
                     
        As of
        September 30,   June 30,
      2016 2016
Backlog            
Energy & Chemicals       $ 113,482     $ 114,562  
Distribution & Storage       246,197     252,502  
BioMedical       24,751     25,433  
Total       $ 384,430     $ 392,497  
                     

CHART INDUSTRIES, INC. AND SUBSIDIARIES
RECONCILIATION OF EARNINGS PER DILUTED SHARE TO ADJUSTED EARNINGS PER DILUTED SHARE (UNAUDITED)
(Dollars in thousands, except per share amounts)
   
  Three Months Ended September 30,
  2016   2015
Earnings per diluted share as reported (U.S. GAAP) $ 0.48     $ 0.15  
Asset impairments 0.04      
Restructuring and acquisition-related costs 0.01     0.05  
Owatonna, MN leased facility shutdown     0.06  
Adjusted earnings per diluted share (Non-GAAP) (1) $ 0.53     $ 0.26  
_______________              
(1)  During the third quarter of 2016, the Company recovered for breaches of representations and warranties primarily related to warranty costs for certain product lines acquired in the 2012 acquisition of AirSep Corporation under the related representation and warranty insurance.  For the three months ended September 30, 2016, this reduced our BioMedical segment's cost of sales by $15,145 and Corporate SG&A by $859, net of associated legal fees, representing $0.52 per share.  We incurred higher than expected warranty costs in the BioMedical segment since the AirSep acquisition in 2012 and as a result, have not adjusted this out for internal purposes as increased expenses were reflected in our operating results in prior periods.
   

Adjusted earnings per diluted share is not a measure of financial performance under U.S. generally accepted accounting principles ("GAAP") and should not be considered as an alternative to earnings per share in accordance with U.S. GAAP.  Management believes that adjusted earnings per share facilitates useful period-to-period comparisons of the Company's financial results and this information is used by the Company in evaluating internal performance.  Chart's calculation of this non-GAAP measure may not be comparable to the calculations of similarly titled measures reported by other companies.
Contact:Ken WebsterVice President andChief Financial Officer216-626-1216ken.webster@chartindustries.com

Primary Logo